Ginkgo Bioworks was awarded a BARDA contract worth up to $22.2 million under the BioMaP‑Consortium to develop cost‑reducing, scalable domestic manufacturing for monoclonal antibodies against filoviruses. Ginkgo will lead partners including Advanced BioScience Laboratories, Isolere Bio, NeuImmune and ProteoNic to advance process innovations covering discovery to production for Emory’s anti‑filovirus antibodies 1C3 and 1C11. The project aims to lower price and speed barriers that impede rapid mAb deployment in outbreaks, aligning with U.S. biosecurity priorities. Ginkgo emphasized integration of novel cell lines, process intensification and modular manufacturing to shrink timelines and costs. BARDA cited the program’s potential to strengthen national preparedness for high‑threat pathogens such as Ebola and Sudan virus.